Authors
Latest:
Fernanda Mesquita, PhD, on Using LAMA2-Exosomes to Improve Cardiomyocyte Survival in StrokeThe research associate at the The Texas Heart Institute discussed preclinical research she presented at AHA’s 2023 Scientific Sessions on MSC-derived exosomes.
Latest:
Chiraag Kapadia on Investigating Clonal Hematopoiesis After CAR T-cell TherapyThe MD, PhD candidate at Baylor College of Medicine discussed findings from a new study presented at the 2023 Tandem Meetings.
Latest:
Mark Forman, MD, PhD, on Genetic Testing and Further Research in Frontotemporal DementiaThe chief medical officer of Passage Bio discussed research needs in FTD.
Latest:
WVU Cancer Institute Cellular Therapy Program Recognized by the Foundation for the Accreditation of Cellular TherapyLauren Veltri, MD Director, WVU Cancer Institute Hematopoietic Malignancy and Cellular Therapy Program, discussed the recent FACT accreditation.
Latest:
Eileen Tzng, BA, on Exploring Exosome and RNA-based Treatment Methods for Heart FailureThe life science research professional at Stanford University discussed preclinical research she presented at the American Heart Association’s Scientific Sessions 2023.
Latest:
James Gulley, MD, PhD, FACP, on Assessing a Novel TCR Bifunctional Antibody in CPI-Resistant Solid TumorsThe director of the Medical Oncology Service at the National Cancer Institute discussed the START-001 trial.
Latest:
CGTLive®’s Weekly Rewind – November 22, 2024Review top news and interview highlights from the week ending November 22, 2024.
Latest:
Deborah Phippard, PhD, on the Challenges of Evaluating Gene Therapy for Parkinson DiseaseThe chief scientific officer of Precision for Medicine discussed unique difficulties of designing clinical trials for PD gene therapy candidates.
Latest:
Performing In-Depth Analysis of Lentiviral Cell Therapies: Luca Biasco, PhDThe director of research and development at AVROBIO discussed the molecular follow-up of cell therapies.
Latest:
Caribou Biosciences' chRDNA Technology May Enable New Treatments for ATTR and Familial HypercholesterolemiaSteve Kanner, PhD, the chief scientific officer of Caribou Biosciences, discussed results from preclinical research evaluating the gene editing approach.
Latest:
Paul Wuh-Liang Hwu, MD, PhD, on Questions Remaining With AADC DeficiencyUpstaza has been granted marketing authorization by the European Commission.
Latest:
CARTITUDE Trials in Multiple MyelomaExperts discussed safety and efficacy data of cilta-cel for R/R MM from the CARTITUDE-1 and CARTITUDE-2 studies.
Latest:
Gene Therapy for APOE4 Homozygous Alzheimer DiseaseR. Nolan Townsend, Sandi See Tai, MD, and Kim G. Johnson, MD, discussed Lexeo Therapeutics’ LX1001 gene therapy trial that demonstrated promising safety and biomarker effects in patients with early-stage Alzheimer disease.
Latest:
Pat Furlong, BSN, RN, on Progress With Research and Advocacy in Muscular DystrophyThe founding president and chief executive officer of Parent Project Muscular Dystrophy discussed how far the field has come since founding the organization/
Latest:
David Barrett, JD, on Future Trends for Genomic MedicinesThe chief executive officer of ASGCT discussed likely future trends extrapolated from the organization’s Q3 Landscape Report.
Latest:
For Cell and Gene Therapies, MCDA Holds Promise for Improving Equity in Value AssessmentAssessing the value of novel therapies has been challenging and controversial using existing methods, pointing to the need for continued exploration of new approaches.
Latest:
Novel Approaches for the Prevention and Treatment of Inflammatory Bone LossCurrent novel therapeutics for the prevention and treatment of bone loss in patients with inflammatory joint disease target cytokines and other inflammatory mediators. Mesenchymal stem cell therapy is a compelling new treatment currently being studied in clinical trials.
Latest:
Trial Initiated to Measure Efficacy of T-Cell Therapy in Secondary Progressive MSOpexa Therapeutics is initiating a phase IIb trial of a novel therapy that targets T-cells in patients with secondary progressive multiple sclerosis.
Latest:
Osiris Wins Canadian Approval for World's First Stem Cell DrugOsiris Therapeutics said it has received approval from Health Canada to market its stem cell therapy Prochymal for the treatment of acute graft-vs-host disease in children.
Latest:
Physicians' Financial News November 2007Physicians' Financial News focuses on newsmaking and/or notable companies in the oncology/biotech sector. In this issue: 1) Pharmion: Oncology-Centered Focus Fuels Continued Pharmion Growth 2) Bristol-Myers Squibb: Treatment-Resistant Breast Cancer Targeted 3) Merger-Mania Poised to Envelop Biotech Sector? 4) GlaxoSmithKline: Oral Therapy Option Offered for Small-Cell Lung Cancer Relapse 5) Immunomedics,Inc.: Immunomedics Wins Pancreatic Cancer Patent 6) ZymoGenetics: Promising Kidney Cancer Therapy Moves Toward Phase II
Latest:
Andrew Russman, DO: Neuroprotection Versus NeurorestorationThe medical director of the Comprehensive Stroke Center at Cleveland Clinic detailed the differences between neuroprotection and neurorestoration, and the available options for each.
Latest:
Stem Cell Therapy in Neurology: An UpdateInsights about where stem cell treatment of neurological diseases is headed.
Latest:
Dr. Villa on Rationale for Examining BR as Induction Therapy in Transplant-Eligible MCLDiego Villa, MD, MPH, discusses the rationale for a retrospective analysis evaluating bendamustine plus rituximab as induction therapy in patients with mantle cell lymphoma.
Latest:
Dr. Balzarotti on Questions With Consolidation and Maintenance Therapy in R/R DLBCLMonica Balzarotti, MD, discusses remaining questions regarding consolidation and maintenance therapy in relapsed/refractory diffuse large B-cell lymphoma.
Latest:
Increasing CAR T-cell Use in R/R DLBC Lymphoma: Marin F. Xavier, MD; John M. Burke, MDExperts discuss recommendations to increase the uptake of CAR T-cell therapies into clinical practice and relapsed/refractory diffuse large B-cell lymphoma.
Latest:
Dr. Patrick M. Forde on Next Steps After CheckMate-026 Study in NSCLCPatrick M. Forde, MBBCh, assistant professor of oncology, Johns Hopkins Hospital, discusses the CheckMate-026 study, which demonstrated that first-line therapy with nivolumab failed to improve progression-free survival (PFS) in PD-L1–positive non-small cell lung cancer (NSCLC) compared with standard chemotherapy.
Latest:
Dr. Gong on Adverse Events of TKI VEGF-Directed Therapy in RCCJun Gong, MD, fellow, City of Hope, discusses adverse events (AEs) associated with TKI/VEGF-directed therapy for patients with metastatic renal cell carcinoma (RCC).
Latest:
Personalized Medicine Moving to Forefront of Hematologic MalignanciesEdward A. Stadtmauer, MD, sheds light on the future of chimeric antigen receptor T-cell therapy, systemic therapeutic advances in the field of acute myeloid leukemia, and remaining challenges in the multiple myeloma paradigm.
Latest:
Dr. Massarelli on First-Line ALK+ NSCLC TreatmentErminia Massarelli, MD, PhD, MS, associate clinical professor, Department of Medical Oncology and Therapeutics Research, City of Hope, discusses the adoption of alectinib (Alecensa) as the first-line therapy in the treatment of patients with ALK-positive non–small cell lung cancer (NSCLC).
Latest:
Dr. Borghaei on the FDA Approval of Nivolumab in Small Cell Lung CancerHossein Borghaei, DO, MS, chief, Division of Thoracic Medical Oncology, director, Lung Cancer Risk Assessment, associate professor, Department of Hematology/Oncology, Fox Chase Cancer Center, discusses the FDA approval of nivolumab (Opdivo) for the treatment of patients with small cell lung cancer with disease progression following 2 or more lines of therapy.
